Janus Henderson Group PLC Centessa Pharmaceuticals PLC Transaction History

Janus Henderson Group PLC

$174 Billion
Q1 2025

A detailed history of Janus Henderson Group PLC transactions in Centessa Pharmaceuticals PLC stock. As of the latest transaction made, Janus Henderson Group PLC holds 5,922,486 shares of CNTA stock, worth $80.4 Million. This represents 0.05% of its overall portfolio holdings.

Number of Shares

5,922,486

Previous 4,909,487 20.63%

Holding current value

$80.4 Million

Previous $82.2 Million 3.57%

% of portfolio

0.05%

Previous 0.04%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	BUY	$14.38 - $19.03 $14.6 Million - $19.3 Million	1,012,999 Added 20.63%	5,922,486 $85.2 Million
Q4 2024 Feb 14, 2025	BUY	$15.04 - $18.67 $54.4 Million - $67.5 Million	3,614,623 Added 279.15%	4,909,487 $82.2 Million
Q3 2024 Nov 14, 2024	BUY	$8.58 - $16.99 $11.1 Million - $22 Million	1,294,864 New	1,294,864 $20.7 Million
Q4 2022 Feb 14, 2023	SELL	$3.05 - $4.19 $2.53 Million - $3.48 Million	-830,437 Reduced 28.2%	2,114,519 $6.56 Million
Q3 2022 Nov 14, 2022	SELL	$3.8 - $5.91 $1.84 Million - $2.86 Million	-483,564 Reduced 14.1%	2,944,956 $11.8 Million
Q2 2022 Aug 15, 2022	SELL	$3.18 - $9.85 $6.96 Million - $21.6 Million	-2,189,299 Reduced 38.97%	3,428,520 $16.7 Million
Q1 2022 May 16, 2022	SELL	$7.45 - $11.59 $935,556 - $1.46 Million	-125,578 Reduced 2.19%	5,617,819 $50.4 Million
Q4 2021 Feb 14, 2022	BUY	$10.99 - $17.54 $1.5 Million - $2.39 Million	136,095 Added 2.43%	5,743,397 $63.1 Million
Q3 2021 Nov 16, 2021	SELL	$16.7 - $23.11 $1.23 Million - $1.7 Million	-73,631 Reduced 1.3%	5,607,302 $91.4 Million
Q2 2021 Aug 16, 2021	BUY	$21.71 - $25.66 $123 Million - $146 Million	5,680,933 New	5,680,933 $120 Million

Others Institutions Holding CNTA

# of Institutions

138

Shares Held

124M

Call Options Held

163K

Put Options Held

338K

View Full List

About Centessa Pharmaceuticals plc

Ticker CNTA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 94,339,296
Market Cap $1.28B
Description
Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its registrational pipeline products include Lixivaptan, a vasopressin V2 receptor small molecule inhibitor that is in Phase III clinical development for the treatment of autosomal dominant polycystic kidney disease; an...

More about CNTA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Janus Henderson Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Janus Henderson Group PLC with notifications on news.

Account

Janus Henderson Group PLC Centessa Pharmaceuticals PLC Transaction History